Which Form?
Rapamycin
Moderate
consensus
Available Forms
- Sirolimus (rapamycin) is a prescription pharmaceutical, not an over-the-counter supplement
- It requires a physician's prescription and monitoring
- FDA-approved for organ transplant rejection prevention
Dosage & Timing
Dosage
- No consensus among the 5 experts
- Attia uses low-dose intermittent protocols in clinical practice but emphasizes there are no clear biomarkers to guide optimal dosing
- Common off-label longevity dosing discussed in the literature is 3-6mg once weekly, but this is not standardized
- Johnson tried multiple dosing protocols before discontinuing entirely
Timing
- Intermittent dosing (typically once weekly) is the approach discussed for longevity use, as opposed to the daily high-dose regimen used in transplant medicine
- The goal is to preferentially inhibit mTORC1 while allowing mTORC2 recovery between doses (Attia)
Expert Positions
What Each Expert Says
Huberman discusses rapamycin across 2 videos with a clear personal stance: he avoids it. In his dedicated longevity supplements AMA, he explicitly states he avoids metformin, berberine, and rapamycin, citing lack of sufficient human data for longevity and the presence of significant side effects. In his interview with Dr. David Fajgenbaum, rapamycin appears in the context of drug repurposing — Fajgenbaum discovered that sirolimus (rapamycin) could treat his terminal Castleman disease, which was originally approved for organ transplant rejection. This episode frames rapamycin as a powerful drug with multiple pathways but does not endorse it for longevity.
Unlock Expert Deep Dives
See exactly which form each expert takes, why they chose it, and their reasoning with video citations.
Cancel anytime